{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:29:06Z","timestamp":1773289746475,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00280-022-04493-5","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T04:20:57Z","timestamp":1672114857000},"page":"143-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3K\u03b4 [14C] SHC014748M in healthy Chinese subjects following oral administration"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-528X","authenticated-orcid":false,"given":"Fei","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuixia","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhou","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqiu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"2","key":"4493_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 68(2):116\u2013132. https:\/\/doi.org\/10.3322\/caac.21438","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4493_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10552-019-01155-5","volume":"30","author":"A Miranda-Filho","year":"2019","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F (2019) Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 30(5):489\u2013499. https:\/\/doi.org\/10.1007\/s10552-019-01155-5","journal-title":"Cancer Causes Control"},{"issue":"7","key":"4493_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/cm9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134(7):783\u2013791. https:\/\/doi.org\/10.1097\/cm9.0000000000001474","journal-title":"Chin Med J (Engl)"},{"issue":"23","key":"4493_CR4","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1182\/blood-2012-12-471094","volume":"121","author":"JF Wise","year":"2013","unstructured":"Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F (2013) Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 121(23):4729\u20134739. https:\/\/doi.org\/10.1182\/blood-2012-12-471094","journal-title":"Blood"},{"issue":"1","key":"4493_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1021\/acscentsci.8b00746","volume":"5","author":"KM Au","year":"2019","unstructured":"Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ (2019) High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci 5(1):122\u2013144. https:\/\/doi.org\/10.1021\/acscentsci.8b00746","journal-title":"ACS Cent Sci"},{"issue":"13","key":"4493_CR6","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","volume":"129","author":"S Gayle","year":"2017","unstructured":"Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T, Rothberg J, Lichenstein H (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129(13):1768\u20131778. https:\/\/doi.org\/10.1182\/blood-2016-09-736892","journal-title":"Blood"},{"key":"4493_CR7","doi-asserted-by":"publisher","first-page":"120338","DOI":"10.1016\/j.biomaterials.2020.120338","volume":"262","author":"C Lee","year":"2020","unstructured":"Lee C, Peddi S, Anderson C, Su H, Cui H, Epstein AL, MacKay JA (2020) Adaptable antibody nanoworms designed for non-Hodgkin lymphoma. Biomaterials 262:120338. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120338","journal-title":"Biomaterials"},{"issue":"9868","key":"4493_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/s0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O\u2019Donoghue D, Boulton-Jones M, Mathieson PW (2013) Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381(9868):744\u2013751. https:\/\/doi.org\/10.1016\/s0140-6736(12)61566-9","journal-title":"Lancet"},{"issue":"7","key":"4493_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2011-04-347518","volume":"119","author":"K O'Callaghan","year":"2012","unstructured":"O\u2019Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L (2012) Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119(7):1717\u20131725. https:\/\/doi.org\/10.1182\/blood-2011-04-347518","journal-title":"Blood"},{"issue":"22","key":"4493_CR10","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1182\/blood-2009-10-251082","volume":"115","author":"AP Bhatt","year":"2010","unstructured":"Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K\/Akt\/mTOR-addicted lymphomas. Blood 115(22):4455\u20134463. https:\/\/doi.org\/10.1182\/blood-2009-10-251082","journal-title":"Blood"},{"issue":"31","key":"4493_CR11","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/jco.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 28(31):4740\u20134746. https:\/\/doi.org\/10.1200\/jco.2010.29.2813","journal-title":"J Clin Oncol"},{"issue":"11","key":"4493_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/leu.2017.80","volume":"31","author":"T Yuan","year":"2017","unstructured":"Yuan T, Yang Y, Chen J, Li W, Li W, Zhang Q, Mi Y, Goswami RS, You JQ, Lin D, Qian MD, Calin S, Liang Y, Miranda RN, Calin GA, Zhou X, Ma L, Zweidler-McKay PA, Liu B, Weng AP, Medeiros LJ, Zhang Y, You MJ (2017) Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN\/Ikaros\/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia 31(11):2355\u20132364. https:\/\/doi.org\/10.1038\/leu.2017.80","journal-title":"Leukemia"},{"issue":"12","key":"4493_CR13","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1084\/jem.20172018","volume":"215","author":"UU Uche","year":"2018","unstructured":"Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D\u2019Cruz LM (2018) PIK3IP1\/TrIP restricts activation of T cells through inhibition of PI3K\/Akt. J Exp Med 215(12):3165\u20133179. https:\/\/doi.org\/10.1084\/jem.20172018","journal-title":"J Exp Med"},{"key":"4493_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-8722-6-8","volume":"6","author":"X Bi","year":"2013","unstructured":"Bi X, Pohl N, Dong H, Yang W (2013) Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc\/p21 mice. J Hematol Oncol 6:8. https:\/\/doi.org\/10.1186\/1756-8722-6-8","journal-title":"J Hematol Oncol"},{"issue":"11","key":"4493_CR15","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/1078-0432.ccr-15-2764","volume":"23","author":"SR Hosford","year":"2017","unstructured":"Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW (2017) Combined inhibition of both p110\u03b1 and p110\u03b2 isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER(+) breast cancer. Clin Cancer Res 23(11):2795\u20132805. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2764","journal-title":"Clin Cancer Res"},{"issue":"26","key":"4493_CR16","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2217\/fon-2020-0195","volume":"16","author":"M Narkhede","year":"2020","unstructured":"Narkhede M, Cheson BD (2020) Copanlisib in the treatment of non-Hodgkin lymphoma. Future Oncol 16(26):1947\u20131955. https:\/\/doi.org\/10.2217\/fon-2020-0195","journal-title":"Future Oncol"},{"issue":"11","key":"4493_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/14656566.2020.1751123","volume":"21","author":"AM Frustaci","year":"2020","unstructured":"Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M (2020) Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother 21(11):1299\u20131309. https:\/\/doi.org\/10.1080\/14656566.2020.1751123","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"4493_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A (2014) Idelalisib: first global approval. Drugs 74(14):1701\u20131707. https:\/\/doi.org\/10.1007\/s40265-014-0285-6","journal-title":"Drugs"},{"issue":"12","key":"4493_CR19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.neo.2020.10.004","volume":"22","author":"L Fan","year":"2020","unstructured":"Fan L, Wang C, Zhao L, Wang Z, Zhang X, Liu X, Cao L, Xu W, Li J (2020) SHC014748M, a novel selective inhibitor of PI3K\u03b4, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia. Neoplasia (New York, NY) 22(12):714\u2013724. https:\/\/doi.org\/10.1016\/j.neo.2020.10.004","journal-title":"Neoplasia (New York, NY)"},{"issue":"3","key":"4493_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1472-8206.2005.00329.x","volume":"19","author":"BW Cheung","year":"2005","unstructured":"Cheung BW, Cartier LL, Russlie HQ, Sawchuk RJ (2005) The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam Clin Pharmacol 19(3):347\u2013354. https:\/\/doi.org\/10.1111\/j.1472-8206.2005.00329.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"4493_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1472-8206.1993.tb00239.x","volume":"7","author":"M Bouvier d'Yvoire","year":"1993","unstructured":"Bouvier d\u2019Yvoire M, Coquerel A, Chretien P, Tremblay D (1993) Pooling plasmas for a rapid answer in pharmacokinetic studies: application to a bioequivalence study of hydrocortisone tablets. Fundam Clin Pharmacol 7(5):253\u2013260. https:\/\/doi.org\/10.1111\/j.1472-8206.1993.tb00239.x","journal-title":"Fundam Clin Pharmacol"},{"key":"4493_CR22","doi-asserted-by":"publisher","unstructured":"Mattsson S, Johansson L, Liniecki J, Nosske D, Stabin M, Leide-Svegborn S, Taylor D (2009) Radiation dose to patients from radiopharmaceuticals, vol 25\/3, pp 474\u2013477. https:\/\/doi.org\/10.1007\/978-3-642-03902-7_134","DOI":"10.1007\/978-3-642-03902-7_134"},{"key":"4493_CR23","doi-asserted-by":"publisher","unstructured":"(2007) The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 37(2\u20134):1\u2013332. https:\/\/doi.org\/10.1016\/j.icrp.2007.10.003","DOI":"10.1016\/j.icrp.2007.10.003"},{"key":"4493_CR24","unstructured":"US Food and Drug Administration (2016) Safety testing\u00a0of\u00a0drugmetabolites\u00a0guidance for industry. http:\/\/www.fda.gov\/down-loads\/drugs\/guidancecomplianceregulatoryinformation\/guid-ances\/ucm079266.pdf. Accessed 22 Nov 2016"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04493-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04493-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T19:20:50Z","timestamp":1675797650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04493-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4493"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04493-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Partial financial support was provided to this study by Sanhome Therapeutics (Nanjing, China). On behalf of all authors, the corresponding author states that they have no conflict of interest regarding the content of the present article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures of this study were approved by the Hospital Ethics Committee and followed the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants in the studies. This study was also approved by China Human Genetic Resources Administration Office (approval\u00a0number\u00a0GH0283) to comply with\u00a0the\u00a0laws\u00a0and policies of the People's Republic of China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}